Nidhi Puranik, Dhananjay Yadav, Pallavi Singh Chauhan, Minseok Kwak* and Jun-O Jin* Pages 11 - 22 ( 12 )
Gene therapy is one of the frontier fields of medical breakthroughs that poses as an effective solution to previously incurable diseases. The delivery of the corrective genetic material or a therapeutic gene into the cell restores the missing gene function and cures a plethora of diseases, incurable by the conventional medical approaches. This discovery holds the potential to treat many neurodegenerative disorders such as muscular atrophy, multiple sclerosis, Parkinson’s disease (PD) and Alzheimer’s disease (AD), among others. Gene therapy proves as a humane, cost-effective alternative to the exhaustive often arduous and timely impossible process of finding matched donors and extensive surgery. It also overcomes the shortcoming of conventional methods to cross the blood-brain barrier. However, the use of gene therapy is only possible after procuring the in-depth knowledge of the immuno-pathogenesis and molecular mechanism of the disease. The process of gene therapy can be broadly categorized into three main steps: elucidating the target gene, culling the appropriate vector, and determining the best mode of transfer; each step mandating pervasive research. This review aims to dissertate and summarize the role, various vectors and methods of delivery employed in gene therapy with special emphasis on therapy directed at the central nervous system (CNS) associated with neurodegenerative diseases.
Gene therapy, neurodegenerative disorder, neuropathy, CNS, AAV, vectors.
Biological Science Department, Bharathiar University, Coimbatore, Tamil Nadu-641046, Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Amity Institute of Biotechnology, Amity University, Gwalior, Madhya Pradesh 474005, Department of Chemistry, Pukyong National University, Busan, Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541